Vesalius Trial
A double-blind, randomized, placebo-controlled, multicentre study to evaluate the impact of Evolocumab on major cardiovascular events in patients at high cardiovascular risk without prior myocardial infarction or stroke.
Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number 2021-0049)
Copyright © CCRE. All Rights Reserved
Centre for Clinical Research and Education
Address: School of Population Health, Curtin University, Bentley WA 6102